Archive

1) Helen Darracott (PAGB)

An introduction to POM to P switching (1.46)

2) John Smith, PAGB

(PAGB President, Wyeth Consumer Healthcare) - An overview of the past and future for switching in the UK – the industry perspective (6.12)

3) Dr June Raine (MHRA)

Moving forward with reclassification – the regulators perspective (7.32)

4) Key Messages

Mike O’Donovan - National Voices, Dr Ian Banks Men’s Health Forum,

Tony Humphreys - EMEA, June Raine -MHRA, Sheila Kelly - PAGB

5) Panel Q1

Should there be only one non prescription category? (1.25)

5) Panel Q2

Are advertising controls needed? (4.29)

5) Panel Q3

An effective boost to switching in Europe (6.55)

5) Panel Q4

Is switching only for the cash rich, time poor? (3.32)

5) Panel Q5

Do we need a super P category? (1.40)

5) Panel Q6

Do we need to continue with switching? (1.32)

5) Panel Q7

Have all the medicines suitable for switching already been switched? (1.50)

5) Panel Q8

Should patients have an equivalent of the BNF? (2.24)

5) Panel Q9

Where will we be after the next 25 years of switching? (3.32)

6) Prof Sir Gordon Duff

(Chairman of the Commission on Human Medicines (CHM)) – Closing speech (2.41)